Diacerein, its beneficial impact on chondrocytes and notable new clinical applications
Autor(a) principal: | |
---|---|
Data de Publicação: | 2018 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Brazilian Journal of Pharmaceutical Sciences |
Texto Completo: | https://www.revistas.usp.br/bjps/article/view/159311 |
Resumo: | Diacerein (DCN) was obtained by diacetylation of an anthraquinone derivative rhein and was approved by FDA in 2008, in the treatment of osteoarthritis due to its inhibitory effect on proinflammatory cytokines, including IL-6 and IL-1β. It was synthesized in 1980s and marketed as a tablet in some European Union and Asian countries from 1994. Along with its great potential in the treatment of osteoarthritis, its other applications are also being explored day by day, such as in the treatment of psoriasis, epidermolysis bullosa, breast cancer, type 2 diabetes and periodontitis. The main aim of this review is to explore mechanism of action, various applications and side effects associated with DCN. This has been reviewed that apart from the risk of diarrhea on long-term administration of DCN, various clinical studies has also shown its modest benefits in treatment of various pathological conditions. Hence, DCN is emerging as a new and potentially safe derivative with maximum therapeutic efficacies and minimum side effects which can results in improving the living status of patients suffering from various inflammatory diseases. |
id |
USP-31_4b181f60e88a07e4c5e28f227a6281d7 |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/159311 |
network_acronym_str |
USP-31 |
network_name_str |
Brazilian Journal of Pharmaceutical Sciences |
repository_id_str |
|
spelling |
Diacerein, its beneficial impact on chondrocytes and notable new clinical applicationsDiacerein/osteoarthritisDrug/chondroprotectiveDiacerein/mechanism of actionDrug/ adverse effectsDiacerein/contraindicationsDiacerein (DCN) was obtained by diacetylation of an anthraquinone derivative rhein and was approved by FDA in 2008, in the treatment of osteoarthritis due to its inhibitory effect on proinflammatory cytokines, including IL-6 and IL-1β. It was synthesized in 1980s and marketed as a tablet in some European Union and Asian countries from 1994. Along with its great potential in the treatment of osteoarthritis, its other applications are also being explored day by day, such as in the treatment of psoriasis, epidermolysis bullosa, breast cancer, type 2 diabetes and periodontitis. The main aim of this review is to explore mechanism of action, various applications and side effects associated with DCN. This has been reviewed that apart from the risk of diarrhea on long-term administration of DCN, various clinical studies has also shown its modest benefits in treatment of various pathological conditions. Hence, DCN is emerging as a new and potentially safe derivative with maximum therapeutic efficacies and minimum side effects which can results in improving the living status of patients suffering from various inflammatory diseases.Universidade de São Paulo. Faculdade de Ciências Farmacêuticas2018-12-20info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/bjps/article/view/15931110.1590/s2175-97902018000417534Brazilian Journal of Pharmaceutical Sciences; Vol. 54 Núm. 4 (2018); e17534Brazilian Journal of Pharmaceutical Sciences; v. 54 n. 4 (2018); e17534Brazilian Journal of Pharmaceutical Sciences; Vol. 54 No. 4 (2018); e175342175-97901984-8250reponame:Brazilian Journal of Pharmaceutical Sciencesinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/bjps/article/view/159311/154102Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciencesinfo:eu-repo/semantics/openAccessKaur, DaljitKaur, JaspreetKamal, Sukhmeet Singh2019-06-24T20:51:54Zoai:revistas.usp.br:article/159311Revistahttps://www.revistas.usp.br/bjps/indexPUBhttps://old.scielo.br/oai/scielo-oai.phpbjps@usp.br||elizabeth.igne@gmail.com2175-97901984-8250opendoar:2019-06-24T20:51:54Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Diacerein, its beneficial impact on chondrocytes and notable new clinical applications |
title |
Diacerein, its beneficial impact on chondrocytes and notable new clinical applications |
spellingShingle |
Diacerein, its beneficial impact on chondrocytes and notable new clinical applications Kaur, Daljit Diacerein/osteoarthritis Drug/chondroprotective Diacerein/mechanism of action Drug/ adverse effects Diacerein/contraindications |
title_short |
Diacerein, its beneficial impact on chondrocytes and notable new clinical applications |
title_full |
Diacerein, its beneficial impact on chondrocytes and notable new clinical applications |
title_fullStr |
Diacerein, its beneficial impact on chondrocytes and notable new clinical applications |
title_full_unstemmed |
Diacerein, its beneficial impact on chondrocytes and notable new clinical applications |
title_sort |
Diacerein, its beneficial impact on chondrocytes and notable new clinical applications |
author |
Kaur, Daljit |
author_facet |
Kaur, Daljit Kaur, Jaspreet Kamal, Sukhmeet Singh |
author_role |
author |
author2 |
Kaur, Jaspreet Kamal, Sukhmeet Singh |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Kaur, Daljit Kaur, Jaspreet Kamal, Sukhmeet Singh |
dc.subject.por.fl_str_mv |
Diacerein/osteoarthritis Drug/chondroprotective Diacerein/mechanism of action Drug/ adverse effects Diacerein/contraindications |
topic |
Diacerein/osteoarthritis Drug/chondroprotective Diacerein/mechanism of action Drug/ adverse effects Diacerein/contraindications |
description |
Diacerein (DCN) was obtained by diacetylation of an anthraquinone derivative rhein and was approved by FDA in 2008, in the treatment of osteoarthritis due to its inhibitory effect on proinflammatory cytokines, including IL-6 and IL-1β. It was synthesized in 1980s and marketed as a tablet in some European Union and Asian countries from 1994. Along with its great potential in the treatment of osteoarthritis, its other applications are also being explored day by day, such as in the treatment of psoriasis, epidermolysis bullosa, breast cancer, type 2 diabetes and periodontitis. The main aim of this review is to explore mechanism of action, various applications and side effects associated with DCN. This has been reviewed that apart from the risk of diarrhea on long-term administration of DCN, various clinical studies has also shown its modest benefits in treatment of various pathological conditions. Hence, DCN is emerging as a new and potentially safe derivative with maximum therapeutic efficacies and minimum side effects which can results in improving the living status of patients suffering from various inflammatory diseases. |
publishDate |
2018 |
dc.date.none.fl_str_mv |
2018-12-20 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/bjps/article/view/159311 10.1590/s2175-97902018000417534 |
url |
https://www.revistas.usp.br/bjps/article/view/159311 |
identifier_str_mv |
10.1590/s2175-97902018000417534 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/bjps/article/view/159311/154102 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas |
publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas |
dc.source.none.fl_str_mv |
Brazilian Journal of Pharmaceutical Sciences; Vol. 54 Núm. 4 (2018); e17534 Brazilian Journal of Pharmaceutical Sciences; v. 54 n. 4 (2018); e17534 Brazilian Journal of Pharmaceutical Sciences; Vol. 54 No. 4 (2018); e17534 2175-9790 1984-8250 reponame:Brazilian Journal of Pharmaceutical Sciences instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Brazilian Journal of Pharmaceutical Sciences |
collection |
Brazilian Journal of Pharmaceutical Sciences |
repository.name.fl_str_mv |
Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
bjps@usp.br||elizabeth.igne@gmail.com |
_version_ |
1800222914411233280 |